(Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention ...
A federal judge on Monday threw out legal challenges to the Medicare negotiation program that had been brought by Bristol Myers Squibb and Johnson & Johnson, finding that their claims of ...
A federal judge in New Jersey rejected Johnson & Johnson and Bristol Myers Squibb's legal challenges to the Biden administration's Medicare drug price negotiations, ruling that the program is ...
Expenses related to acquisitions recently weighed down Bristol Myers' earnings results. The company, however, still generates strong free cash flow. Its high debt load could turn off some risk ...
Bristol Myers Squibb Bristol Myers Squibb (NYSE: BMY) recently reported its Q1 results, with revenues and earnings above the street estimates. The company reported revenue of $11.9 billion and an ...
Bristol Myers Squibb said on Friday that its trial evaluating a combination of cancer treatments failed to meet its primary endpoint. The company’s trial was evaluating the cancer-drug Opdivo ...
A federal judge has dismissed legal challenges to the Medicare negotiation program brought by Bristol Myers Squibb and Johnson & Johnson, ruling that their claims of unconstitutionality are unfounded.